|Tesis Doctorales de la Universidad de Alcalá
|C3 CONVERTASE AS A NOVEL BIOMARKER OF CARDIOVASCULAR PATHOLOGY, INSULIN RESISTANCE AND ENDOTHELIAL DYSFUNCTION|
|Autor/a||Rodriguez Guerrero, Aranzazu|
|Departamento||Biología de Sistemas|
|Director/a||Sabán Ruiz, José|
|Fecha de defensa||17/07/2017|
|Calificación||Sobresaliente Cum Laude|
|Programa||Ciencias de la Salud (RD 99/2011)|
|Resumen||ntroduction: Atherothrombotic disease is the leading aetiology of mortality in the Western countries. Its main cause is not hypercholesterolemia but the Metabolic Syndrome (MetS). In the last three decades MetS evolved from a quintet (hyperglycaemia, hypertension, hypertriglyceridemia, low HDL and waist) to become an octet named Cardiometabolic Syndrome (CMS), where the triad, consisting of inflammation/metaflammation, oxidative stress (OS) and endothelial dysfunction (ED) is essential to understand its impact at the vascular level. Insulin resistance (IR) is located at the heart of both syndromes. From the inflammatory point of view, the most used marker has been the CRP with the inconvenience of being highly unspecific. Finding new markers has become the researchers¿ goal for the last years. The present work confirms that the C3 convertase in plasma can be useful as a marker and possibly as a pathogenic factor, which if confirmed, would postulate C3 as a target of future preventive strategies.
Objectives: Assess the behaviour of C3 convertase, key enzyme that controls the complement cascade in relation to MetS, CMS including ED, IR and cardiovascular (CV) risk in a population referred to cardiometabolic secondary care.
Methodology: An observational retrospective cross-sectional study was performed on a random cohort of adult individuals from Madrid. Specific cardiometabolic factors were measured as part of the clinical routine of the Cardiometabolic Unit. CV risk was calculated by REGICOR formula. IR was estimated by HOMA-IR formula in a non-exogenous insulin replacement group. Subjects were stratified by C3 complement quartiles to assess the distribution of the cardiometabolic markers. Multivariable regression analysis was applied to identify predictors of C3 variability.
Results: A total of n=374 subjects were selected (53.60±14.80 yr. old, 44.9% females), where 65% were hypertensive, 42% hyperglycaemic and 35% MetS. C3 complement levels were associated with: 1. MetS: MetS diagnosis, each single MetS criterion, proportional number of MetS criteria and new MetS criteria (p|